AnalystsEvan David Seigerman
Evan David Seigerman's Stock Forecasts

Analyst Ranking
Top 29%
#1413 out of 4929 analysts
Average Return
+4.72%
Win Rate
36%15 out of 42
Risk vs Reward
Poor
Good

Evan David Seigerman's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Candel Therapeutics IncCADL
+568.75%$1.60$10.70
2023-05-15 -
2024-05-14
Buy
Morphic Holding IncMORF
+147.53%$22.49$55.67
2023-09-28 -
2024-07-09
Buy
Eli Lilly & CoLLY
+81.93%$306.82$558.19
2022-09-06 -
2023-09-05
Buy
Regeneron Pharmaceuticals IncREGN
+41.20%$844.37$1,192.23
2023-08-21 -
2024-08-20
Buy
Abbvie IncABBV
+19.08%$161.52$192.34
2024-04-29 -
2025-04-28
Buy

Evan David Seigerman's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Neurogene IncNGNE
2Buy$26.00+29.42%Maintains
23 days ago
Regeneron Pharmaceuticals IncREGN
7Buy$600.00+9.62%Maintains
a month ago
Merus NvMRUS
1Buy$110.00+104.38%Maintains
a month ago
Acadia Pharmaceuticals IncACAD
1Buy$28.00+33.65%Maintains
2 months ago
Arvinas IncARVN
1Buy$10.00+25.79%Maintains
2 months ago
Novo Nordisk A SNVO
6Hold$64.00-7.47%Downgrades
3 months ago
Merck & Co IncMRK
4Hold$96.00+18.62%Maintains
5 months ago
Abbvie IncABBV
7Buy$215.00+13.59%Maintains
5 months ago
Amgen IncAMGN
4Buy$346.00+16.01%Maintains
5 months ago
Replimune Group IncREPL
3Buy$27.00+187.23%Maintains
5 months ago
Morphic Holding IncMORF
3Hold$57.00+0.02%Downgrades
a year ago
Structure Therapeutics IncGPCR
2Buy$100.00N/AMaintains
a year ago
Pfizer IncPFE
4Buy$36.00N/AReiterates
a year ago
Mirati Therapeutics IncMRTX
4Hold$72.00N/AMaintains
2 years ago
Candel Therapeutics IncCADL
1Buy$3.00N/AMaintains
2 years ago
Eli Lilly & CoLLY
1Buy$396.00N/AMaintains
3 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.